# Protein methyltransferases as a target class for drug dis

Nature Reviews Drug Discovery

8, 724-732

DOI: 10.1038/nrd2974

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Copper-Mediated Amidation of Heterocyclic and Aromatic Câ^'H Bonds. Organic Letters, 2009, 11, 5178-5180. | 2.4 | 293 |
| 2 | A Chloroacetamidineâ€Based Inactivator of Protein Arginine Methyltransferase 1: Design, Synthesis, and In Vitro and In Vivo Evaluation. ChemBioChem, 2010, 11, 1219-1223. | 1.3 | 38 |
| 3 | Targeting epigenetic enzymes for drug discovery. Current Opinion in Chemical Biology, 2010, 14, 505-510. | 2.8 | 99 |
| 4 | Accessing Protein Methyltransferase and Demethylase Enzymology Using Microfluidic Capillary Electrophoresis. Chemistry and Biology, 2010, 17, 695-704. | 6.2 | 41 |
| 5 | Toward the development of potent and selective bisubstrate inhibitors of protein arginine methyltransferases. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2103-2105. | 1.0 | 53 |
| 6 | Structural Biology of Human H3K9 Methyltransferases. PLoS ONE, 2010, 5, e8570. | 1.1 | 218 |
| 7 | Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20980-20985. | 3.3 | 608 |
| 8 | Structural genomics of histone tail recognition. Bioinformatics, 2010, 26, 2629-2630. | 1.8 | 9 |
| 9 | EZH2 does it. Science-Business EXchange, 2010, 3, 1401-1401. | 0.0 | 0 |
| 10 | Kinetics of Re-establishing H3K79 Methylation Marks in Global Human Chromatin*. Journal of Biological Chemistry, 2010, 285, 32778-32786. | 1.6 | 56 |
| 11 | Epigenetic therapy: targeting histones and their modifications in human disease. Future Medicinal Chemistry, 2010, 2, 543-548. | 1.1 | 11 |
| 12 | Epigenetics: tools and technologies. Drug Discovery Today: Technologies, 2010, 7, e59-e65. | 4.0 | 28 |
| 13 | Epigenetic control of the immune system: histone demethylation as a target for drug discovery. Drug Discovery Today: Technologies, 2010, 7, e67-e75. | 4.0 | 8 |
| 14 | Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development. Expert Opinion on Therapeutic Targets, 2010, 14, 405-418. | 1.5 | 42 |
| 15 | Targeting Methyl Lysine. Annual Reports in Medicinal Chemistry, 2010, 45, 329-343. | 0.5 | 9 |
| 16 | Nî-Substituted Arginyl Peptide Inhibitors of Protein Arginine N-Methyltransferases. ACS Chemical Biology, 2010, 5, 1053-1063. | 1.6 | 34 |
| 17 | Adding a Lysine Mimic in the Design of Potent Inhibitors of Histone Lysine Methyltransferases. Journal of Molecular Biology, 2010, 400, 1-7. | 2.0 | 108 |
| 18 | Small molecule modulators of histone acetylation and methylation: A disease perspective. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2010, 1799, 810-828. | 0.9 | 45 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Protein Lysine Methyltransferase G9a Inhibitors: Design, Synthesis, and Structure Activity Relationships of 2,4-Diamino-7-aminoalkoxy-quinazolines.. Journal of Medicinal Chemistry, 2010, 53, 5844-5857. | 2.9 | 177 |
| 20 | A combinatorial approach to characterize the substrate specificity of proteinargininemethyltransferase 1. Molecular BioSystems, 2011, 7, 48-51. | 2.9 | 23 |
| 21 | Small molecule inhibitors that discriminate between protein arginine N-methyltransferases PRMT1 and CARM1. Organic and Biomolecular Chemistry, 2011, 9, 7814. | 1.5 | 36 |
| 22 | Promises and challenges of anticancer drugs that target the epigenome. Epigenomics, 2011, 3, 547-565. | 1.0 | 21 |
| 23 | Biochemical Characterization of Human SET and MYND Domain-Containing Protein 2 Methyltransferase. Biochemistry, 2011, 50, 6488-6497. | 1.2 | 43 |
| 24 | Florigen takes two to tango. Nature Chemical Biology, 2011, 7, 665-666. | 3.9 | 3 |
| 25 | Fluorescence polarization assays in small molecule screening. Expert Opinion on Drug Discovery, 2011, 6, 17-32. | 2.5 | 285 |
| 26 | Selective Inhibitors of Histone Methyltransferase DOT1L: Design, Synthesis, and Crystallographic Studies. Journal of the American Chemical Society, 2011, 133, 16746-16749. | 6.6 | 144 |
| 27 | Structural Chemistry of the Histone Methyltransferases Cofactor Binding Site. Journal of Chemical Information and Modeling, 2011, 51, 612-623. | 2.5 | 76 |
| 28 | Balancing histone methylation activities in psychiatric disorders. Trends in Molecular Medicine, 2011, 17, 372-379. | 3.5 | 100 |
| 29 | A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nature Chemical Biology, 2011, 7, 566-574. | 3.9 | 465 |
| 30 | Facile synthesis of N-6 adenosine modified analogue toward S-adenosyl methionine derived probe for protein arginine methyltransferases. Chinese Chemical Letters, 2011, 22, 1439-1442. | 4.8 | 8 |
| 31 | Epigenetic Multiple Modulators. Current Topics in Medicinal Chemistry, 2011, 11, 2749-2787. | 1.0 | 11 |
| 32 | Chemogenetic Analysis of Human Protein Methyltransferases. Chemical Biology and Drug Design, 2011, 78, 199-210. | 1.5 | 167 |
| 33 | Regulation of chromatin by histone modifications. Cell Research, 2011, 21, 381-395. | 5.7 | 4,442 |
| 34 | Structural Basis of Substrate Methylation and Inhibition of SMYD2. Structure, 2011, 19, 1262-1273. | 1.6 | 176 |
| 35 | Sharpen your epigenetic tools. Nature Chemical Biology, 2011, 7, 499-500. | 3.9 | 5 |
| 36 | Small-Molecule Ligands of Methyl-Lysine Binding Proteins. Journal of Medicinal Chemistry, 2011, 54, 2504-2511. | 2.9 | 115 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Optimization of Cellular Activity of G9a Inhibitors 7-Aminoalkoxy-quinazolines. Journal of Medicinal Chemistry, 2011, 54, 6139-6150. | 2.9 | 127 |
| 38 | Total syntheses of chaetocin and ent-chaetocin. Tetrahedron, 2011, 67, 6587-6599. | 1.0 | 60 |
| 39 | Structure and Function of Histone H3 Lysine 9 Methyltransferases and Demethylases. ChemBioChem, 2011, 12, 254-263. | 1.3 | 75 |
| 40 | Peptidic Partial Bisubstrates as Inhibitors of the Protein Arginine Nâ€Methyltransferases. ChemBioChem, 2011, 12, 1427-1432. | 1.3 | 22 |
| 41 | Epizyme: Plying the Epigenome's Enzymes. Chemistry and Biology, 2011, 18, 403-404. | 6.2 | 1 |
| 42 | Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors. Bioorganic and Medicinal Chemistry, 2011, 19, 3709-3716. | 1.4 | 87 |
| 43 | Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics, 2011, 3, 581-609. | 1.0 | 97 |
| 44 | Dengue Drug Discovery. Topics in Medicinal Chemistry, 2011, , 243-275. | 0.4 | 2 |
| 45 | Small Molecule Inhibitors That Selectively Block Dengue Virus Methyltransferase. Journal of Biological Chemistry, 2011, 286, 6233-6240. | 1.6 | 147 |
| 46 | TR-FRET Cellular Assays for Interrogating Posttranslational Modifications of Histone H3. Journal of Biomolecular Screening, 2011, 16, 1236-1246. | 2.6 | 27 |
| 47 | Targeting leukemia on the DOT. Nature Chemical Biology, 2011, 7, 663-665. | 3.9 | 6 |
| 48 | Clicking class B GPCR ligands. Nature Chemical Biology, 2011, 7, 500-501. | 3.9 | 5 |
| 49 | Development and Validation of a Generic Fluorescent Methyltransferase Activity Assay Based on the Transcreener AMP/GMP Assay. Journal of Biomolecular Screening, 2012, 17, 59-70. | 2.6 | 19 |
| 50 | Crystal structure of the human PRMT5:MEP50 complex. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17960-17965. | 3.3 | 261 |
| 51 | An enzyme-coupled high-throughput assay for screening RNA methyltransferase activity inE. Colicell lysate. RNA Biology, 2012, 9, 577-586. | 1.5 | 19 |
| 52 | DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences. Expert Opinion on Drug Discovery, 2012, 7, 1039-1051. | 2.5 | 21 |
| 53 | Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16708-16713. | 3.3 | 117 |
| 54 | Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1. Cancer Discovery, 2012, 2, 798-811. | 7.7 | 432 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Identification of Small-Molecule Enhancers of Arginine Methylation Catalyzed by Coactivator-Associated Arginine Methyltransferase 1. Journal of Medicinal Chemistry, 2012, 55, 9875-9890. | 2.9 | 22 |
| 56 | Sinefungin Derivatives as Inhibitors and Structure Probes of Protein Lysine Methyltransferase SETD2. Journal of the American Chemical Society, 2012, 134, 18004-18014. | 6.6 | 119 |
| 57 | A Method for Large-scale Identification of Protein Arginine Methylation. Molecular and Cellular Proteomics, 2012, 11, 1489-1499. | 2.5 | 122 |
| 58 | A High Throughput Scintillation Proximity Imaging Assay for Protein Methyltransferases. Combinatorial Chemistry and High Throughput Screening, 2012, 15, 359-371. | 0.6 | 25 |
| 59 | A complex Polycomb issue: the two faces of EZH2 in cancer. Genes and Development, 2012, 26, 751-755. | 2.7 | 110 |
| 60 | Trials with â€˜epigeneticâ€™ drugs: An update. Molecular Oncology, 2012, 6, 657-682. | 2.1 | 208 |
| 61 | Sâ€Adenosylâ€Methionineâ€Dependent Methyltransferases: Highly Versatile Enzymes in Biocatalysis, Biosynthesis and Other Biotechnological Applications. ChemBioChem, 2012, 13, 2642-2655. | 1.3 | 335 |
| 62 | Toxoplasmahistone acetylation remodelers as novel drug targets. Expert Review of Anti-Infective Therapy, 2012, 10, 1189-1201. | 2.0 | 47 |
| 63 | Analogues of the HIV-Tat peptide containing Nî·-modified arginines as potent inhibitors of protein arginine N-methyltransferases. MedChemComm, 2012, 3, 1235. | 3.5 | 11 |
| 64 | Supramolecular hosts that recognize methyllysines and disrupt the interaction between a modified histone tail and its epigenetic reader protein. Chemical Science, 2012, 3, 2695. | 3.7 | 70 |
| 65 | Chronic Pain: Emerging Evidence for the Involvement of Epigenetics. Neuron, 2012, 73, 435-444. | 3.8 | 240 |
| 66 | An Allosteric Inhibitor of Protein Arginine Methyltransferase 3. Structure, 2012, 20, 1425-1435. | 1.6 | 80 |
| 67 | Development of second generation epigenetic agents. MedChemComm, 2012, 3, 135-161. | 3.5 | 16 |
| 68 | Emerging Epigenetic Targets and Therapies in Cancer Medicine. Cancer Discovery, 2012, 2, 405-413. | 7.7 | 106 |
| 69 | Cell signaling, post-translational protein modifications and NMR spectroscopy. Journal of Biomolecular NMR, 2012, 54, 217-236. | 1.6 | 153 |
| 70 | A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nature Chemical Biology, 2012, 8, 890-896. | 3.9 | 698 |
| 71 | Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L. Chemical Biology and Drug Design, 2012, 80, 971-980. | 1.5 | 132 |
| 72 | Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nature Communications, 2012, 3, 1288. | 5.8 | 247 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Stopping a chromatin enzyme. Nature Chemical Biology, 2012, 8, 875-876. | 3.9 | 7 |
| 74 | Protein methyltransferase inhibitors as personalized cancer therapeutics. Drug Discovery Today: Therapeutic Strategies, 2012, 9, e83-e90. | 0.5 | 16 |
| 75 | Future strategies in epigenetic drug discovery. Drug Discovery Today: Therapeutic Strategies, 2012, 9, e121-e127. | 0.5 | 10 |
| 76 | RB1 Methylation by SMYD2 Enhances Cell Cycle Progression through an Increase of RB1 Phosphorylation. Neoplasia, 2012, 14, 476-IN8. | 2.3 | 169 |
| 77 | Synthesis and Structureâ€“Activity Relationship Investigation of Adenosine-Containing Inhibitors of Histone Methyltransferase DOT1L. Journal of Medicinal Chemistry, 2012, 55, 8066-8074. | 2.9 | 84 |
| 79 | Current limitations and future opportunities for epigenetic therapies. Future Medicinal Chemistry, 2012, 4, 425-446. | 1.1 | 38 |
| 80 | Reactivation of the Tumour Suppressor RASSF1A in Breast Cancer by Simultaneous Targeting of DNA and E2F1 Methylation. PLoS ONE, 2012, 7, e52231. | 1.1 | 27 |
| 81 | Approval of New Agents after Phase II Trials. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , e1-e3. | 1.8 | 3 |
| 82 | Current Chemical Biology Approaches to Interrogate Protein Methyltransferases. ACS Chemical Biology, 2012, 7, 443-463. | 1.6 | 121 |
| 83 | Epigenetic protein families: a new frontier for drug discovery. Nature Reviews Drug Discovery, 2012, 11, 384-400. | 21.5 | 1,161 |
| 84 | Site-Specific Mapping and Time-Resolved Monitoring of Lysine Methylation by High-Resolution NMR Spectroscopy. Journal of the American Chemical Society, 2012, 134, 7616-7619. | 6.6 | 50 |
| 85 | Epigenetics: Concepts and relevance to IBD pathogenesis. Inflammatory Bowel Diseases, 2012, 18, 1982-1996. | 0.9 | 50 |
| 86 | Epigenetic mechanisms in neurological disease. Nature Medicine, 2012, 18, 1194-1204. | 15.2 | 394 |
| 87 | Efficient Hit-Finding Approaches for Histone Methyltransferases: The Key Parameters. Journal of Biomolecular Screening, 2012, 17, 85-98. | 2.6 | 5 |
| 88 | Small-Molecule Inhibitors of the Protein Methyltransferase SET7/9 Identified in a High-Throughput Screen. Journal of Biomolecular Screening, 2012, 17, 1102-1109. | 2.6 | 13 |
| 89 | Detecting S-adenosyl-l-methionine-induced conformational change of a histone methyltransferase using a homogeneous time-resolved fluorescence-based binding assay. Analytical Biochemistry, 2012, 423, 171-177. | 1.1 | 15 |
| 90 | Mass spectrometry-based identification and characterisation of lysine and arginine methylation in the human proteome. Molecular BioSystems, 2013, 9, 2231. | 2.9 | 141 |
| 91 | Nuclear receptors and epigenetic signaling: Novel regulators of glycogen metabolism in skeletal muscle. IUBMB Life, 2013, 65, 657-664. | 1.5 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 92 | Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes: a patent evaluation (WO2012075381). Expert Opinion on Therapeutic Patents, 2013, 23, 537-543. | 2.4 | 4 |
| 93 | Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases. Nature Chemical Biology, 2013, 9, 136-137. | 3.9 | 95 |
| 94 | The Mind and its Nucleosomes â€“ Chromatin (dys)Regulation in Major Psychiatric Disease. , 2013, , 197-222. | | 0 |
| 95 | Drugging the human methylome: an emerging modality for reversible control of aberrant gene transcription. Current Opinion in Chemical Biology, 2013, 17, 369-378. | 2.8 | 21 |
| 96 | A Medicinal Chemistry Perspective for Targeting Histone H3 Lysine-79 Methyltransferase DOT1L. Journal of Medicinal Chemistry, 2013, 56, 8972-8983. | 2.9 | 62 |
| 97 | Active site specific pharmacophore-based screening forÂmethyltransferase inhibitors. Journal of Pharmacy Research, 2013, 7, 121-126. | 0.4 | 2 |
| 98 | A Novel Selective LSD1/KDM1A Inhibitor Epigenetically Blocks Herpes Simplex Virus Lytic Replication and Reactivation from Latency. MBio, 2013, 4, e00558-12. | 1.8 | 114 |
| 99 | On the Histone Lysine Methyltransferase Activity of Fungal Metabolite Chaetocin. Journal of Medicinal Chemistry, 2013, 56, 8616-8625. | 2.9 | 54 |
| 100 | Discovery of an in Vivo Chemical Probe of the Lysine Methyltransferases G9a and GLP. Journal of Medicinal Chemistry, 2013, 56, 8931-8942. | 2.9 | 220 |
| 101 | Enzyme-Dependent Lysine Deprotonation in EZH2 Catalysis. Biochemistry, 2013, 52, 6866-6878. | 1.2 | 20 |
| 102 | Elements of the Polycomb Repressor SU(Z)12 Needed for Histone H3-K27 Methylation, the Interface with E(Z), and In Vivo Function. Molecular and Cellular Biology, 2013, 33, 4844-4856. | 1.1 | 29 |
| 103 | Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome. Journal of Hematology and Oncology, 2013, 6, 58. | 6.9 | 2 |
| 104 | A journey toward Bioorthogonal Profiling of Protein Methylation inside living cells. Current Opinion in Chemical Biology, 2013, 17, 729-737. | 2.8 | 38 |
| 105 | Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases. Quarterly Reviews of Biophysics, 2013, 46, 349-373. | 2.4 | 28 |
| 106 | An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy. Neuropharmacology, 2013, 68, 2-82. | 2.0 | 190 |
| 107 | Conservation and Functional Importance of Carbonâ€“Oxygen Hydrogen Bonding in AdoMet-Dependent Methyltransferases. Journal of the American Chemical Society, 2013, 135, 15536-15548. | 6.6 | 92 |
| 108 | Molecular Pathways: Protein Methyltransferases in Cancer. Clinical Cancer Research, 2013, 19, 6344-6350. | 3.2 | 56 |
| 109 | Histone methyltransferase MLL3 contributes to genome-scale circadian transcription. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1554-1559. | 3.3 | 107 |

| # | Article | IF | Citations |
|---|---|---|---|
| 110 | Synthesis, activity and metabolic stability of non-ribose containing inhibitors of histone methyltransferase DOT1L. MedChemComm, 2013, 4, 822. | 3.5 | 31 |
| 111 | Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer. Future Medicinal Chemistry, 2013, 5, 1661-1670. | 1.1 | 11 |
| 112 | Perspectives on natural product epigenetic modulators in chemical biology and medicine. Natural Product Reports, 2013, 30, 605. | 5.2 | 52 |
| 113 | Small-molecular modulators of cancer-associated epigenetic mechanisms. Molecular BioSystems, 2013, 9, 873. | 2.9 | 42 |
| 114 | Exploiting an Allosteric Binding Site of PRMT3 Yields Potent and Selective Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 2110-2124. | 2.9 | 64 |
| 115 | Epigenetic Determinants of Healthy and Diseased Brain Aging and Cognition. JAMA Neurology, 2013, 70, 711. | 4.5 | 72 |
| 116 | Assay Development for Histone Methyltransferases. Assay and Drug Development Technologies, 2013, 11, 227-236. | 0.6 | 67 |
| 117 | An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chemical Biology, 2013, 8, 1324-1334. | 1.6 | 399 |
| 118 | Strategy to Target the Substrate Binding site of SET Domain Protein Methyltransferases. Journal of Chemical Information and Modeling, 2013, 53, 681-691. | 2.5 | 18 |
| 119 | Novel symmetrical ureas as modulators of protein arginine methyl transferases. Bioorganic and Medicinal Chemistry, 2013, 21, 2056-2067. | 1.4 | 18 |
| 120 | Modulation of Epigenetic Targets for Anticancer Therapy: Clinicopathological Relevance, Structural Data and Drug Discovery Perspectives. Current Pharmaceutical Design, 2013, 19, 578-613. | 0.9 | 69 |
| 121 | Drug discovery in academic institutions. Hematology American Society of Hematology Education Program, 2013, 2013, 300-305. | 0.9 | 2 |
| 122 | Targeting protein arginineN-methyltransferases with peptide-based inhibitors: opportunities and challenges. Future Medicinal Chemistry, 2013, 5, 2199-2206. | 1.1 | 10 |
| 123 | Writing and Rewriting the Epigenetic Code of Cancer Cells: From Engineered Proteins to Small Molecules. Molecular Pharmacology, 2013, 83, 563-576. | 1.0 | 30 |
| 124 | Smallâ€Molecule Modulators for Epigenetics Targets. ChemMedChem, 2013, 8, 1885-1891. | 1.6 | 19 |
| 125 | Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics. Oncogene, 2013, 32, 939-946. | 2.6 | 66 |
| 126 | Histone Methyltransferase Inhibitors: Novel Epigenetic Agents for Cancer Treatment. Current Medicinal Chemistry, 2013, 20, 167-185. | 1.2 | 56 |
| 127 | Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. PLoS ONE, 2014, 9, e111840. | 1.1 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 128 | Regeneration competence accompanies increased expression of arginine methyltransferase PRMT8 in human adult fibroblasts. , 2014, , . | | 0 |
| 129 | Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 9235-9240. | 3.3 | 60 |
| 130 | Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma. Molecular Cancer Therapeutics, 2014, 13, 842-854. | 1.9 | 457 |
| 131 | EZH2: biology, disease, and structure-based drug discovery. Acta Pharmacologica Sinica, 2014, 35, 161-174. | 2.8 | 168 |
| 132 | Characterization of the histone methyltransferase PRDM9 using biochemical, biophysical and chemical biology techniques. Biochemical Journal, 2014, 461, 323-334. | 1.7 | 30 |
| 133 | Cyclosporines: Biosynthesis and Beyond. Fungal Biology, 2014, , 65-88. | 0.3 | 3 |
| 134 | Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: <scp>IUPHAR</scp> Review 11. British Journal of Pharmacology, 2014, 171, 4981-5010. | 2.7 | 23 |
| 135 | Histone methylases as novel drug targets: developing inhibitors of EZH2. Future Medicinal Chemistry, 2014, 6, 1943-1965. | 1.1 | 11 |
| 136 | Nonâ€radioactive Protein Lysine Methyltransferase Microplate Assay Based on Reading Domains. ChemMedChem, 2014, 9, 554-559. | 1.6 | 7 |
| 137 | Histone Methyltransferases: Opportunities in Cancer Drug Discovery. , 2014, , 189-226. | | 1 |
| 138 | Chromatin-regulating proteins as targets for cancer therapy. Journal of Radiation Research, 2014, 55, 613-628. | 0.8 | 28 |
| 139 | Gfi-1 is the transcriptional repressor ofSOCS1in acute myeloid leukemia cells. Journal of Leukocyte Biology, 2013, 95, 105-115. | 1.5 | 17 |
| 140 | Loss of histone H4K20 trimethylation predicts poor prognosis in breast cancer and is associated with invasive activity. Breast Cancer Research, 2014, 16, R66. | 2.2 | 75 |
| 141 | Using â€˜biased-privilegedâ€™ scaffolds to identify lysine methyltransferase inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 2253-2260. | 1.4 | 13 |
| 142 | Chromatin-bound RNA and the neurobiology of psychiatric disease. Neuroscience, 2014, 264, 131-141. | 1.1 | 8 |
| 143 | Role of the histone <scp>H</scp>3 lysineÂ9 methyltransferase <scp>S</scp>uv39Âh1 in maintaining <scp>E</scp>psteinnâ€“<scp>B</scp>arr virus latency in <scp>B</scp>95â€“8 cells. FEBS Journal, 2014, 281, 2148-2158. | 2.2 | 28 |
| 144 | Computational Analysis of Methyl Transfer Reactions in Dengue Virus Methyltransferase. Journal of Physical Chemistry B, 2014, 118, 5882-5890. | 1.2 | 11 |
| 145 | The emerging role of epigenetics in rheumatic diseases. Rheumatology, 2014, 53, 406-414. | 0.9 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 146 | Genome-wide localization of small molecules. Nature Biotechnology, 2014, 32, 92-96. | 9.4 | 165 |
| 147 | Targeting Chromatin Modifying Enzymes in Anticancer Drug Discovery. , 2014, , 239-256. | | 0 |
| 148 | Astemizole Arrests the Proliferation of Cancer Cells by Disrupting the EZH2-EED Interaction of Polycomb Repressive Complex 2. Journal of Medicinal Chemistry, 2014, 57, 9512-9521. | 2.9 | 96 |
| 149 | Structural biology and chemistry of protein arginine methyltransferases. MedChemComm, 2014, 5, 1779-1788. | 3.5 | 71 |
| 150 | Structureâ€“activity relationship studies of SETD8 inhibitors. MedChemComm, 2014, 5, 1892-1898. | 3.5 | 28 |
| 151 | A Basic Post-SET Extension of NSDs Is Essential for Nucleosome Binding In Vitro. Journal of Biomolecular Screening, 2014, 19, 928-935. | 2.6 | 34 |
| 152 | Discovery of a Selective, Substrate-Competitive Inhibitor of the Lysine Methyltransferase SETD8. Journal of Medicinal Chemistry, 2014, 57, 6822-6833. | 2.9 | 81 |
| 153 | A Fragment-Based Approach to Identifying S-Adenosyl-<scp>l</scp>-methionine -Competitive Inhibitors of Catechol O-Methyl Transferase (COMT).. Journal of Medicinal Chemistry, 2014, 57, 5459-5463. | 2.9 | 9 |
| 154 | Structural insights into binding of small molecule inhibitors to Enhancer of Zeste Homolog 2. Journal of Computer-Aided Molecular Design, 2014, 28, 1109-1128. | 1.3 | 3 |
| 155 | Small-Molecule Inhibitors of SETD8 with Cellular Activity. ACS Chemical Biology, 2014, 9, 2471-2478. | 1.6 | 54 |
| 156 | Small Molecule Control of Chromatin Remodeling. Chemistry and Biology, 2014, 21, 1196-1210. | 6.2 | 55 |
| 157 | Natural compounds in epigenetics: A current view. Food and Chemical Toxicology, 2014, 73, 71-83. | 1.8 | 35 |
| 158 | CARMA: CARM1 Methylation of SWI/SNF in Breast Cancer. Cancer Cell, 2014, 25, 3-4. | 7.7 | 14 |
| 159 | Use of Epigenetic Drugs in Disease: An Overview. Genetics & Epigenetics, 2014, 6, GEG.S12270. | 2.5 | 260 |
| 160 | Redefining metamorphosis in spiny lobsters: molecular analysis of the phyllosoma to puerulus transition in Sagmariasus verreauxi. Scientific Reports, 2015, 5, 13537. | 1.6 | 43 |
| 161 | Structural diversity of the epigenetics pocketome. Proteins: Structure, Function and Bioinformatics, 2015, 83, 1316-1326. | 1.5 | 9 |
| 162 | Direct Reversal Repair in Mammalian Cells. , 0, , . | | 3 |
| 163 | Synthesis of lysine methyltransferase inhibitors. Frontiers in Chemistry, 2015, 3, 44. | 1.8 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 164 | EZH2 in Bladder Cancer, a Promising Therapeutic Target. International Journal of Molecular Sciences, 2015, 16, 27107-27132. | 1.8 | 57 |
| 165 | MoSET1 (Histone H3K4 Methyltransferase in Magnaporthe oryzae) Regulates Global Gene Expression during Infection-Related Morphogenesis. PLoS Genetics, 2015, 11, e1005385. | 1.5 | 69 |
| 166 | The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia. PLoS ONE, 2015, 10, e0131716. | 1.1 | 65 |
| 167 | Progress and challenges in predicting protein methylation sites. Molecular BioSystems, 2015, 11, 2610-2619. | 2.9 | 11 |
| 168 | Enzymatic Assays of Histone Methyltransferase Enzymes. , 2015, , 333-361. | | 5 |
| 169 | Comparison of a High-Throughput Mass Spectrometry Method and Radioactive Filter Binding to Assay the Protein Methyltransferase PRMT5. Assay and Drug Development Technologies, 2015, 13, 235-240. | 0.6 | 12 |
| 170 | The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond. Cellular and Molecular Life Sciences, 2015, 72, 2041-2059. | 2.4 | 364 |
| 171 | Digging deep into â€œdirtyâ€•drugs â€“ modulation of the methylation machinery. Drug Metabolism Reviews, 2015, 47, 252-279. | 1.5 | 63 |
| 172 | Chemical Probes of Histone Lysine Methyltransferases. ACS Chemical Biology, 2015, 10, 40-50. | 1.6 | 46 |
| 173 | Regulation of CD4 Tâ€cell differentiation and inflammation by repressive histone methylation. Immunology and Cell Biology, 2015, 93, 245-252. | 1.0 | 18 |
| 174 | Selective Inhibitors of Protein Methyltransferases. Journal of Medicinal Chemistry, 2015, 58, 1596-1629. | 2.9 | 112 |
| 175 | Methyltransferases do not work by compression, cratic, or desolvation effects, but by electrostatic preorganization. Proteins: Structure, Function and Bioinformatics, 2015, 83, 318-330. | 1.5 | 58 |
| 176 | A SMYD3 Smallâ€Molecule Inhibitor Impairing Cancer Cell Growth. Journal of Cellular Physiology, 2015, 230, 2447-2460. | 2.0 | 95 |
| 177 | Mediation of donorâ€“acceptor distance in an enzymatic methyl transfer reaction. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7954-7959. | 3.3 | 65 |
| 178 | WHSC1 Promotes Oncogenesis through Regulation of NIMA-Related Kinase-7 in Squamous Cell Carcinoma of the Head and Neck. Molecular Cancer Research, 2015, 13, 293-304. | 1.5 | 82 |
| 179 | Biochemical Assay Development for Histone Methyltransferases Using a Transcreener-Based Assay for S-Adenosylhomocysteine. Assay and Drug Development Technologies, 2015, 13, 200-209. | 0.6 | 8 |
| 180 | High-throughput screening-compatible assays of As(III) S-adenosylmethionine methyltransferase activity. Analytical Biochemistry, 2015, 480, 67-73. | 1.1 | 11 |
| 181 | Computer-aided Molecular Design of Compounds Targeting Histone Modifying Enzymes. Computational and Structural Biotechnology Journal, 2015, 13, 358-365. | 1.9 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 182 | Chemical Biology of Protein Arginine Modifications in Epigenetic Regulation. Chemical Reviews, 2015, 115, 5413-5461. | 23.0 | 224 |
| 183 | EPMA position paper in cancer: current overview and future perspectives. EPMA Journal, 2015, 6, 9. | 3.3 | 86 |
| 184 | Discovery and Optimization of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Pharmacophore- and Docking-Based Virtual Screening. Journal of Medicinal Chemistry, 2015, 58, 8166-8181. | 2.9 | 59 |
| 185 | Epigenetic-based therapy: From single- to multi-target approaches. International Journal of Biochemistry and Cell Biology, 2015, 69, 121-131. | 1.2 | 40 |
| 186 | Identification of a functional hotspot on ubiquitin required for stimulation of methyltransferase activity on chromatin. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 10365-10370. | 3.3 | 44 |
| 187 | Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010â€“2014). Pharmaceutical Patent Analyst, 2015, 4, 261-284. | 0.4 | 36 |
| 188 | Crystal structure of Legionella pneumophila type IV secretion system effector LegAS4. Biochemical and Biophysical Research Communications, 2015, 465, 817-824. | 1.0 | 8 |
| 189 | A Chemical Proteomics Approach for Global Analysis of Lysine Monomethylome Profiling *. Molecular and Cellular Proteomics, 2015, 14, 329-339. | 2.5 | 58 |
| 190 | Targeting the epigenetic machinery of cancer cells. Oncogene, 2015, 34, 135-143. | 2.6 | 48 |
| 191 | Synthesis and evaluation of protein arginine N-methyltransferase inhibitors designed to simultaneously occupy both substrate binding sites. Organic and Biomolecular Chemistry, 2015, 13, 549-560. | 1.5 | 45 |
| 192 | Targeting Histone Methylation. , 2016, , 209-238. | | 1 |
| 193 | Novel Protein Arginine Methyltransferase 8 Isoform Is Essential for Cell Proliferation. Journal of Cellular Biochemistry, 2016, 117, 2056-2066. | 1.2 | 20 |
| 194 | Discovery and Development of Small Molecules Targeting Epigenetic Enzymes with Computational Methods. , 2016, , 75-112. | | 4 |
| 195 | Methyltransferase-Glo: a universal, bioluminescent and homogenous assay for monitoring all classes of methyltransferases. Epigenomics, 2016, 8, 321-339. | 1.0 | 80 |
| 196 | Epigenetic polypharmacology: from combination therapy to multitargeted drugs. Clinical Epigenetics, 2016, 8, 105. | 1.8 | 113 |
| 197 | Plasmodium falciparum PfSET7: enzymatic characterization and cellular localization of a novel protein methyltransferase in sporozoite, liver and erythrocytic stage parasites. Scientific Reports, 2016, 6, 21802. | 1.6 | 27 |
| 198 | Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. Journal of Hematology and Oncology, 2016, 9, 49. | 6.9 | 124 |
| 199 | Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity. Future Medicinal Chemistry, 2016, 8, 879-897. | 1.1 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 200 | Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clinical Epigenetics, 2016, 8, 57. | 1.8 | 333 |
| 201 | Current Development of Protein Arginine Methyltransferase Inhibitors. , 2016, , 231-256. | | 3 |
| 202 | Molecular Design of Compounds Targeting Histone Methyltransferases. , 2016, , 257-272. | | 4 |
| 203 | Synthesis and Assays of Inhibitors of Methyltransferases. Methods in Enzymology, 2016, 574, 245-308. | 0.4 | 21 |
| 204 | Pharmacological inhibition of arginine and lysine methyltransferases induces nuclear abnormalities and suppresses angiogenesis in human endothelial cells. Biochemical Pharmacology, 2016, 121, 18-32. | 2.0 | 17 |
| 205 | Chemical Proteomic Profiling of Human Methyltransferases. Journal of the American Chemical Society, 2016, 138, 13335-13343. | 6.6 | 79 |
| 206 | The emerging role of lysine methyltransferase SETD8 in human diseases. Clinical Epigenetics, 2016, 8, 102. | 1.8 | 77 |
| 207 | Design, synthesis, and protein methyltransferase activity of a unique set of constrained amine containing compounds. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4436-4440. | 1.0 | 8 |
| 208 | Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 8306-8325. | 2.9 | 53 |
| 209 | Chemical Inhibition of Protein Methyltransferases. Cell Chemical Biology, 2016, 23, 1067-1076. | 2.5 | 40 |
| 210 | Histone lysine methyltransferases as anti-cancer targets for drug discovery. Acta Pharmacologica Sinica, 2016, 37, 1273-1280. | 2.8 | 28 |
| 211 | Progress in the Development of Lysine Methyltransferase SETD8 Inhibitors. ChemMedChem, 2016, 11, 1680-1685. | 1.6 | 18 |
| 212 | Rewiring the solid tumor epigenome for cancer therapy. Expert Review of Anticancer Therapy, 2016, 16, 977-987. | 1.1 | 7 |
| 213 | Global Proteomics Analysis of Protein Lysine Methylation. Current Protocols in Protein Science, 2016, 86, 24.8.1-24.8.19. | 2.8 | 23 |
| 214 | Structure-Based Design of a Covalent Inhibitor of the SET Domain-Containing Protein 8 (SETD8) Lysine Methyltransferase. Journal of Medicinal Chemistry, 2016, 59, 9881-9889. | 2.9 | 35 |
| 215 | Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation. Biomedicine and Pharmacotherapy, 2016, 81, 288-294. | 2.5 | 22 |
| 216 | Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach. ACS Medicinal Chemistry Letters, 2016, 7, 735-740. | 1.3 | 53 |
| 217 | Chromodomain Ligand Optimization via Target-Class Directed Combinatorial Repurposing. ACS Chemical Biology, 2016, 11, 2475-2483. | 1.6 | 46 |

| # | Article | IF | Citations |
|---|---|---|---|
| 218 | Understanding the Complexity of Epigenetic Target Space. Journal of Medicinal Chemistry, 2016, 59, 1299-1307. | 2.9 | 29 |
| 219 | Facile synthesis of SAMâ€“peptide conjugates through alkyl linkers targeting protein N-terminal methyltransferase 1. RSC Advances, 2016, 6, 6768-6771. | 1.7 | 18 |
| 220 | Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives. Journal of Medicinal Chemistry, 2016, 59, 1357-1369. | 2.9 | 52 |
| 221 | Role of Histone-Modifying Enzymes and Their Complexes in Regulation of Chromatin Biology. Biochemistry, 2016, 55, 1584-1599. | 1.2 | 80 |
| 222 | PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease. Biochemistry, 2016, 55, 1600-1614. | 1.2 | 104 |
| 223 | Characterization of the Enzymatic Activity of SETDB1 and Its 1:1 Complex with ATF7IP. Biochemistry, 2016, 55, 1645-1651. | 1.2 | 16 |
| 224 | CARM1 Preferentially Methylates H3R17 over H3R26 through a Random Kinetic Mechanism. Biochemistry, 2016, 55, 1635-1644. | 1.2 | 35 |
| 225 | Molecular Evolution of the Substrate Specificity of Chloroplastic Aldolases/Rubisco Lysine Methyltransferases in Plants. Molecular Plant, 2016, 9, 569-581. | 3.9 | 19 |
| 226 | Identification of Novel Disruptor of Telomeric Silencing 1-like (DOT1L) Inhibitors through Structure-Based Virtual Screening and Biological Assays. Journal of Chemical Information and Modeling, 2016, 56, 527-534. | 2.5 | 27 |
| 227 | Targeting Epigenetic Mechanisms for Chronic Pain: A Valid Approach for the Development of Novel Therapeutics. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 84-93. | 1.3 | 36 |
| 228 | Epigenetics: A primer for clinicians. Blood Reviews, 2016, 30, 285-295. | 2.8 | 42 |
| 229 | Chemical Inhibitors of Epigenetic Methyllysine Reader Proteins. Biochemistry, 2016, 55, 1570-1583. | 1.2 | 36 |
| 230 | Epigenome-based personalized medicine in human cancer. Epigenomics, 2016, 8, 119-133. | 1.0 | 76 |
| 231 | 3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1. Journal of Medicinal Chemistry, 2016, 59, 253-263. | 2.9 | 76 |
| 232 | SAM/SAH Analogs as Versatile Tools for SAM-Dependent Methyltransferases. ACS Chemical Biology, 2016, 11, 583-597. | 1.6 | 177 |
| 233 | Miniaturization of High-Throughput Epigenetic Methyltransferase Assays with Acoustic Liquid Handling. Journal of the Association for Laboratory Automation, 2016, 21, 208-216. | 2.8 | 10 |
| 234 | Epigenetics in cancer stem cells. Molecular Cancer, 2017, 16, 29. | 7.9 | 296 |
| 235 | Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy. Journal of Medicinal Chemistry, 2017, 60, 2215-2226. | 2.9 | 86 |

| # | Article | IF | Citations |
|---|---|---|---|
| 236 | Noncoupled Fluorescent Assay for Direct Real-Time Monitoring of Nicotinamide N-Methyltransferase Activity. Biochemistry, 2017, 56, 824-832. | 1.2 | 24 |
| 237 | A chemical probe toolbox for dissecting the cancer epigenome. Nature Reviews Cancer, 2017, 17, 160-183. | 12.8 | 76 |
| 238 | Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors using a Target-Specific Scoring Function for the (S)-Adenosyl-<scp>l</scp>-methionine (SAM)-Dependent Methyltransferase Family. Journal of Medicinal Chemistry, 2017, 60, 2026-2036. | 2.9 | 22 |
| 239 | Die Methyltransferaseâ€gesteuerte Markierung von BiomolekÃ¼len und ihre Anwendungen. Angewandte Chemie, 2017, 129, 5266-5285. | 1.6 | 13 |
| 240 | A direct label-free MALDI-TOF mass spectrometry based assay for the characterization of inhibitors of protein lysine methyltransferases. Analytical and Bioanalytical Chemistry, 2017, 409, 3767-3777. | 1.9 | 22 |
| 241 | Structure of the PRC2 complex and application to drug discovery. Acta Pharmacologica Sinica, 2017, 38, 963-976. | 2.8 | 35 |
| 242 | Structureâ€“Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase. Journal of Medicinal Chemistry, 2017, 60, 5015-5028. | 2.9 | 53 |
| 243 | Protein post-translational modifications: In silico prediction tools and molecular modeling. Computational and Structural Biotechnology Journal, 2017, 15, 307-319. | 1.9 | 145 |
| 244 | Histone lysine methyltransferase structure activity relationships that allow for segregation of G9a inhibition and anti-Plasmodium activity. MedChemComm, 2017, 8, 1069-1092. | 3.5 | 24 |
| 245 | Methyltransferaseâ€Directed Labeling of Biomolecules and its Applications. Angewandte Chemie - International Edition, 2017, 56, 5182-5200. | 7.2 | 60 |
| 246 | The story of protein arginine methylation: characterization, regulation, and function. Expert Review of Proteomics, 2017, 14, 157-170. | 1.3 | 63 |
| 247 | Strategy Based on Deglycosylation, Multiprotease, and Hydrophilic Interaction Chromatography for Large-Scale Profiling of Protein Methylation. Analytical Chemistry, 2017, 89, 12909-12917. | 3.2 | 24 |
| 248 | Drug Discovery and Chemical Biology of Cancer Epigenetics. Cell Chemical Biology, 2017, 24, 1120-1147. | 2.5 | 47 |
| 249 | DNA and Histone Modifications in Cancer Therapy. Cancer Drug Discovery and Development, 2017, , 585-604. | 0.2 | 0 |
| 250 | An affinity-based probe for methyltransferase enzymes based on sinefungin. Canadian Journal of Chemistry, 2017, 95, 1059-1063. | 0.6 | 2 |
| 251 | Selective Reagent for Detection of Nâ€Monomethylation of a Peptide Lysine Residue through S<sub>N</sub>Ar Reaction. European Journal of Organic Chemistry, 2017, 2017, 3606-3611. | 1.2 | 1 |
| 252 | Lysine Possesses the Optimal Chain Length for Histone Lysine Methyltransferase Catalysis. Scientific Reports, 2017, 7, 16148. | 1.6 | 21 |
| 253 | A comprehensive review of lysine-specific demethylase 1 and its roles in cancer. Epigenomics, 2017, 9, 1123-1142. | 1.0 | 125 |

| # | Article | IF | Citations |
|---|---|---|---|
| 254 | Recent progress in developing selective inhibitors of protein methyltransferases. Current Opinion in Chemical Biology, 2017, 39, 100-108. | 2.8 | 40 |
| 255 | Reprogramming of <scp>mPFC</scp> transcriptome and function in alcohol dependence. Genes, Brain and Behavior, 2017, 16, 86-100. | 1.1 | 38 |
| 256 | Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations. Chemical Biology and Drug Design, 2017, 89, 585-598. | 1.5 | 22 |
| 257 | Inhibitors of Epigenetic Regulation in Cancer. , 2017, , 281-307. | | 1 |
| 258 | Histone Lysine Methylation and Neurodevelopmental Disorders. International Journal of Molecular Sciences, 2017, 18, 1404. | 1.8 | 53 |
| 259 | Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1. PLoS ONE, 2017, 12, e0170301. | 1.1 | 12 |
| 260 | Arginine Methylation by PRMT2 Controls the Functions of the Actin Nucleator Cobl. Developmental Cell, 2018, 45, 262-275.e8. | 3.1 | 34 |
| 261 | Methylation of Elongation Factor 1A: Where, Who, and Why?. Trends in Biochemical Sciences, 2018, 43, 211-223. | 3.7 | 52 |
| 262 | Effects of histone methyltransferase inhibition in endometriosisâ€. Biology of Reproduction, 2018, 99, 293-307. | 1.2 | 20 |
| 263 | Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches. Journal of Computer-Aided Molecular Design, 2018, 32, 435-458. | 1.3 | 15 |
| 264 | Direct Detection of Products from S-Adenosylmethionine-Dependent Enzymes Using a Competitive Fluorescence Polarization Assay. Analytical Chemistry, 2018, 90, 1740-1747. | 3.2 | 8 |
| 265 | Dual role of autophagy in hallmarks of cancer. Oncogene, 2018, 37, 1142-1158. | 2.6 | 403 |
| 266 | Targeting of epigenetic regulators in neuroblastoma. Experimental and Molecular Medicine, 2018, 50, 1-12. | 3.2 | 34 |
| 267 | Detection of PRMT1 inhibitors with stopped flow fluorescence. Signal Transduction and Targeted Therapy, 2018, 3, 6. | 7.1 | 8 |
| 268 | Inhibitors of Protein Methyltransferases and Demethylases. Chemical Reviews, 2018, 118, 989-1068. | 23.0 | 222 |
| 269 | Vitamin C â€“ A new player in regulation of the cancer epigenome. Seminars in Cancer Biology, 2018, 51, 59-67. | 4.3 | 73 |
| 270 | Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology, 2018, 147, 141-152. | 2.0 | 56 |
| 271 | Upregulation of PRMT6 by LPS suppresses Klotho expression through interaction with NFâ€ÎºB in glomerular mesangial cells. Journal of Cellular Biochemistry, 2018, 119, 3404-3416. | 1.2 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 272 | The methylation induced by protein arginine methyltransferase 5 promotes tumorigenesis and progression of lung cancer. Journal of Thoracic Disease, 2018, 10, 7014-7019. | 0.6 | 3 |
| 273 | Biocatalytic methylation and demethylation via a shuttle catalysis concept involving corrinoid proteins. Communications Chemistry, 2018, 1, . | 2.0 | 27 |
| 274 | Enhancer RNA and NFÎºB-dependent P300 regulation of ADAMDEC1. Molecular Immunology, 2018, 103, 312-321. | 1.0 | 16 |
| 275 | Target Identification Using Chemical Probes. Methods in Enzymology, 2018, 610, 27-58. | 0.4 | 9 |
| 276 | Six Years (2012â€“2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2â€Pyridone Compounds. Chemical Record, 2018, 18, 1818-1832. | 2.9 | 76 |
| 277 | Identification of protoberberine alkaloids as novel histone methyltransferase G9a inhibitors by structure-based virtual screening. Journal of Computer-Aided Molecular Design, 2018, 32, 917-928. | 1.3 | 12 |
| 278 | MT-MAMS: Protein Methyltransferase Motif Analysis by Mass Spectrometry. Journal of Proteome Research, 2018, 17, 3485-3491. | 1.8 | 23 |
| 279 | RNA-modifying proteins as anticancer drug targets. Nature Reviews Drug Discovery, 2018, 17, 435-453. | 21.5 | 107 |
| 280 | Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy. Expert Opinion on Therapeutic Targets, 2018, 22, 527-545. | 1.5 | 40 |
| 281 | Epigenetics in ovarian cancer: premise, properties, and perspectives. Molecular Cancer, 2018, 17, 109. | 7.9 | 87 |
| 282 | Chemical Denaturation and Protein Precipitation Approach for Discovery and Quantitation of Proteinâ€“Drug Interactions. Analytical Chemistry, 2018, 90, 9249-9255. | 3.2 | 40 |
| 283 | Design, synthesis and anti leukemia cells proliferation activities of pyrimidylaminoquinoline derivatives as DOT1L inhibitors. Bioorganic Chemistry, 2018, 80, 649-654. | 2.0 | 11 |
| 284 | Proteobacterial Origin of Protein Arginine Methylation and Regulation of Complex I Assembly by MidA. Cell Reports, 2018, 24, 1996-2004. | 2.9 | 10 |
| 285 | Kinetic Mechanism of Nicotinamide N-Methyltransferase. Biochemistry, 2018, 57, 5524-5532. | 1.2 | 33 |
| 286 | Protein methyltransferase inhibitors as precision cancer therapeutics: a decade of discovery. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373, 20170080. | 1.8 | 34 |
| 287 | Epigenetic Drug Discovery for Alzheimerâ€™s Disease. , 2018, , 453-495. | | 9 |
| 288 | Chemical and Biochemical Perspectives of Protein Lysine Methylation. Chemical Reviews, 2018, 118, 6656-6705. | 23.0 | 167 |
| 289 | Delineating the active site architecture of G9a lysine methyltransferase through substrate and inhibitor binding mode analysis: a molecular dynamics study. Journal of Biomolecular Structure and Dynamics, 2019, 37, 2581-2592. | 2.0 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 290 | Insights for the design of protein lysine methyltransferase G9a inhibitors. Future Medicinal Chemistry, 2019, 11, 993-1014. | 1.1 | 23 |
| 291 | Preparation of 4â€²â€Spirocyclobutyl Nucleoside Analogues as Novel and Versatile Adenosine Scaffolds. Chemistry - A European Journal, 2019, 25, 15419-15423. | 1.7 | 10 |
| 292 | <p>Effect of <em>SMYD3</em> on biological behavior and H3K4 methylation in bladder cancer</p>. Cancer Management and Research, 2019, Volume 11, 8125-8133. | 0.9 | 8 |
| 293 | Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling. Acta Pharmacologica Sinica, 2019, 40, 1067-1075. | 2.8 | 29 |
| 294 | Methyltransferaseâ€like 21e inhibits 26S proteasome activity to facilitate hypertrophy of type IIb myofibers. FASEB Journal, 2019, 33, 9672-9684. | 0.2 | 9 |
| 295 | Novel SAR for quinazoline inhibitors of EHMT1 and EHMT2. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2516-2524. | 1.0 | 2 |
| 296 | Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends. Future Medicinal Chemistry, 2019, 11, 901-921. | 1.1 | 29 |
| 297 | Epigenetically Down-Regulated Acetyltransferase PCAF Increases the Resistance of Colorectal Cancer to 5-Fluorouracil. Neoplasia, 2019, 21, 557-570. | 2.3 | 28 |
| 298 | The BAF complex in development and disease. Epigenetics and Chromatin, 2019, 12, 19. | 1.8 | 155 |
| 299 | Identification, Quantification, and System Analysis of Protein Nâ€ε Lysine Methylation in Anucleate Blood Platelets. Proteomics, 2019, 19, e1900001. | 1.3 | 7 |
| 300 | Negative Ion Mode Collision-Induced Dissociation for Analysis of Protein Arginine Methylation. Journal of the American Society for Mass Spectrometry, 2019, 30, 1229-1241. | 1.2 | 5 |
| 301 | Discovery of a chemical probe for PRDM9. Nature Communications, 2019, 10, 5759. | 5.8 | 24 |
| 302 | Methyltransferase Inhibitors: Competing with, or Exploiting the Bound Cofactor. Molecules, 2019, 24, 4492. | 1.7 | 36 |
| 303 | Emerging impacts of biological methylation on genetic information. Journal of Biochemistry, 2019, 165, 9-18. | 0.9 | 15 |
| 304 | A chemical biology toolbox to study protein methyltransferases and epigenetic signaling. Nature Communications, 2019, 10, 19. | 5.8 | 113 |
| 305 | Virtual Screening with a Structure-Based Pharmacophore Model to Identify Small-Molecule Inhibitors of CARM1. Journal of Chemical Information and Modeling, 2019, 59, 522-534. | 2.5 | 8 |
| 306 | Polycomb complexes in normal and malignant hematopoiesis. Journal of Cell Biology, 2019, 218, 55-69. | 2.3 | 52 |
| 307 | Identification of novel quinoline inhibitor for EHMT2/G9a through virtual screening. Biochimie, 2020, 168, 220-230. | 1.3 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 308 | Acetylation dependent functions of Rab22a-NeoF1 Fusion Protein in Osteosarcoma. Theranostics, 2020, 10, 7747-7757. | 4.6 | 11 |
| 309 | Impact of epigenetic modifiers on the immune system. , 2020, , 315-352. | | 0 |
| 310 | Asymmetric Total Synthesis of C9â€²-epi-Sinefungin. Organic Letters, 2020, 22, 5594-5599. | 2.4 | 6 |
| 311 | Lead discovery, chemical optimization, and biological evaluation studies of novel histone methyltransferase SET7 small-molecule inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127061. | 1.0 | 11 |
| 312 | Exploring Chloride Selectivity and Halogenase Regioselectivity of the SalL Enzyme through Quantum Mechanical/Molecular Mechanical Modeling. Journal of Chemical Information and Modeling, 2020, 60, 738-746. | 2.5 | 14 |
| 313 | Modifications of histones in parasites as drug targets. Veterinary Parasitology, 2020, 278, 109029. | 0.7 | 6 |
| 314 | Targeting epigenetics in cancer: therapeutic potential of flavonoids. Critical Reviews in Food Science and Nutrition, 2021, 61, 1616-1639. | 5.4 | 38 |
| 315 | Pharmacophore-based screening of diamidine small molecule inhibitors for protein arginine methyltransferases. RSC Medicinal Chemistry, 2021, 12, 95-102. | 1.7 | 3 |
| 316 | Predictive QM/MM Modeling of Modulations in Proteinâ€“Protein Binding by Lysine Methylation. Journal of Molecular Biology, 2021, 433, 166745. | 2.0 | 9 |
| 317 | The Contribution of Transcriptional Coregulators in the Maintenance of Î²-cell Function and Identity. Endocrinology, 2021, 162, . | 1.4 | 3 |
| 318 | Dysregulation of the histone demethylase KDM6B in alcohol dependence is associated with epigenetic regulation of inflammatory signaling pathways. Addiction Biology, 2021, 26, e12816. | 1.4 | 28 |
| 319 | Computer-aided screening for suppressor of variegation 4-20 homolog 1 inhibitors and their preliminary activity validation in human osteosarcoma. Journal of Biomolecular Structure and Dynamics, 2021, 39, 526-537. | 2.0 | 4 |
| 320 | Investigational new drugs against glioblastoma. , 2021, , 31-77. | | 0 |
| 321 | SUV39H1 is a New Client Protein of Hsp90 Degradated by Chaetocin as a Novel C-Terminal Inhibitor of Hsp90. Biomolecules and Therapeutics, 2021, 29, 73-82. | 1.1 | 4 |
| 323 | Design and Characterization of a Pyridone-Containing EZH2 Inhibitor Phosphate Prodrug. Journal of Medicinal Chemistry, 2021, 64, 1725-1732. | 2.9 | 11 |
| 324 | Autophagy Plays a Role in the CUL4A-Related Poor Prognosis of Intrahepatic Cholangiocarcinoma. Pathology and Oncology Research, 2021, 27, 602714. | 0.9 | 0 |
| 325 | How Does Protein Nutrition Affect the Epigenetic Changes in Pig? A Review. Animals, 2021, 11, 544. | 1.0 | 10 |
| 326 | The link among microbiota, epigenetics, and disease development. Environmental Science and Pollution Research, 2021, 28, 28926-28964. | 2.7 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 327 | Methylation as a key regulator of Tau aggregation and neuronal health in Alzheimerâ€™s disease. Cell Communication and Signaling, 2021, 19, 51. | 2.7 | 24 |
| 328 | Role of chromatin modulation in the establishment of protozoan parasite infection for developing targeted chemotherapeutics. Nucleus (India), 0, , 1. | 0.9 | 2 |
| 329 | Methylâ€Induced Polarization Destabilizes the Noncovalent Interactions of Nâ€Methylated Lysines. Chemistry - A European Journal, 2021, 27, 11005-11014. | 1.7 | 5 |
| 330 | Microbiota and epigenetics: promising therapeutic approaches?. Environmental Science and Pollution Research, 2021, 28, 49343-49361. | 2.7 | 15 |
| 331 | Targeting WD Repeat-Containing Protein 5 (WDR5): A Medicinal Chemistry Perspective. Journal of Medicinal Chemistry, 2021, 64, 10537-10556. | 2.9 | 25 |
| 332 | Systems pharmacology dissection of action mechanisms for herbs in osteoporosis treatment. Chinese Herbal Medicines, 2021, 13, 313-331. | 1.2 | 4 |
| 333 | Functional Interplay between Methyltransferases and Inflammasomes in Inflammatory Responses and Diseases. International Journal of Molecular Sciences, 2021, 22, 7580. | 1.8 | 10 |
| 334 | A Lightâ€Controllable Chemical Modulation of m 6 A RNA Methylation. Angewandte Chemie, 2021, 133, 18264-18269. | 1.6 | 5 |
| 335 | A Lightâ€Controllable Chemical Modulation of m<sup>6</sup>A RNA Methylation. Angewandte Chemie - International Edition, 2021, 60, 18116-18121. | 7.2 | 23 |
| 336 | Analysing the essential proteins set of Plasmodium falciparum PF3D7 for novel drug targets identification against malaria. Malaria Journal, 2021, 20, 335. | 0.8 | 8 |
| 337 | Nano DNA Vaccine Encoding Toxoplasma gondii Histone Deacetylase SIR2 Enhanced Protective Immunity in Mice. Pharmaceutics, 2021, 13, 1582. | 2.0 | 3 |
| 338 | Discovery of a Non-Nucleoside SETD2 Methyltransferase Inhibitor against Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2021, 22, 10055. | 1.8 | 7 |
| 339 | An update on allosteric modulators as a promising strategy targeting histone methyltransferase. Pharmacological Research, 2021, 172, 105865. | 3.1 | 5 |
| 340 | Recent Progress in the Discovery of Epigenetic Inhibitors for the Treatment of Cancer. Methods in Molecular Biology, 2015, 1238, 677-688. | 0.4 | 8 |
| 341 | Histone Methyltransferase Activity Assays. RSC Drug Discovery Series, 2015, , 267-287. | 0.2 | 2 |
| 343 | Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease. Journal of Clinical Investigation, 2017, 127, 2751-2764. | 3.9 | 84 |
| 344 | Identification of 6-(piperazin-1-yl)-1,3,5-triazine as a chemical scaffold with broad anti-schistosomal activities. Wellcome Open Research, 2020, 5, 169. | 0.9 | 7 |
| 345 | Identification of 6-(piperazin-1-yl)-1,3,5-triazine as a chemical scaffold with broad anti-schistosomal activities. Wellcome Open Research, 2020, 5, 169. | 0.9 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 346 | HEMD: An Integrated Tool of Human Epigenetic Enzymes and Chemical Modulators for Therapeutics. PLoS ONE, 2012, 7, e39917. | 1.1 | 25 |
| 347 | Epigenetic arginine methylation in breast cancer: emerging therapeutic strategies. Journal of Molecular Endocrinology, 2019, 62, R223-R237. | 1.1 | 30 |
| 348 | Inhibition of Nuclear Receptor Binding SET Domain 2/ Multiple Myeloma SET Domain by LEM-06 Implication for Epigenetic Cancer Therapies. Journal of Cancer Prevention, 2015, 20, 113-120. | 0.8 | 27 |
| 349 | NT1721, a novel epidithiodiketopiperazine, exhibits potent in vitro and in vivo efficacy against acute myeloid leukemia. Oncotarget, 2016, 7, 86186-86197. | 0.8 | 10 |
| 350 | Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer. Oncotarget, 2014, 5, 10665-10677. | 0.8 | 78 |
| 351 | Genome-wide multi-omics profiling of the 8p11-p12 amplicon in breast carcinoma. Oncotarget, 2018, 9, 24140-24154. | 0.8 | 19 |
| 352 | SUV420H1 enhances the phosphorylation and transcription of ERK1 in cancer cells. Oncotarget, 2015, 6, 43162-43171. | 0.8 | 28 |
| 353 | Lysine Methyltransferases Signaling: Histones are Just the Tip of the Iceberg. Current Protein and Peptide Science, 2020, 21, 655-674. | 0.7 | 13 |
| 354 | Targets in Epigenetics: Inhibiting the Methyl Writers of the Histone Code. Current Chemical Genomics, 2011, 5, 72-84. | 2.0 | 52 |
| 355 | Structural Chemistry of Human SET Domain Protein Methyltransferases. Current Chemical Genomics, 2011, 5, 85-94. | 2.0 | 84 |
| 356 | Investigation of hub genes and their nonsynonymous single nucleotide polymorphism analysis in Plasmodium falciparum for designing therapeutic methodologies using next-generation sequencing approach. Indian Journal of Pharmacology, 2019, 51, 389. | 0.4 | 1 |
| 357 | Chapter 5. Chemical Biology of Histone Modifications. RSC Drug Discovery Series, 2010, , 151-203. | 0.2 | 0 |
| 358 | Protein Methyltransferases as Targets for Personalized Cancer Therapeutics. AACR Education Book, 2012, 2012, 107-112. | 0.0 | 1 |
| 359 | Histone Methyltransferase Complexes in Transcription, Development, and Cancer. , 2014, , 33-47. | | 0 |
| 360 | Molecular Approaches to Explore Natural and Food-Compound Modulators in Cancer Epigenetics and Metabolism. , 2014, , 131-149. | | 0 |
| 361 | Rapid Advances in the Field of Epigenetics. Translational Bioinformatics, 2014, , 193-223. | 0.0 | 0 |
| 363 | Targeting Histone Lysine Methyltransferases in Cancer. RSC Drug Discovery Series, 2015, , 127-167. | 0.2 | 0 |
| 364 | Positioning of an unprecedented 1,5-oxaza spiroquinone scaffold into SMYD2 inhibitors in epigenetic space. European Journal of Medicinal Chemistry, 2022, 227, 113880. | 2.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 365 | Regio- and Stereoselective Synthesis of C-4â€² Spirocyclobutyl Ribofuranose Scaffolds and Their Use as Biologically Active Nucleoside Analogues. Organic Letters, 2021, 23, 8828-8833. | 2.4 | 5 |
| 367 | The critical role of histone lysine demethylase KDM2B in cancer. American Journal of Translational Research (discontinued), 2018, 10, 2222-2233. | 0.0 | 31 |
| 368 | Fascinating Transformation of SAM-Competitive Protein Methyltransferase Inhibitors from Nucleoside Analogues to Non-Nucleoside Analogues. Journal of Medicinal Chemistry, 2022, 65, 1662-1684. | 2.9 | 11 |
| 369 | DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 1948-1965. | 3.2 | 21 |
| 370 | Preferential Self-interaction of DNA Methyltransferase DNMT3A Subunits Containing the R882H Cancer Mutation Leads to Dominant Changes of Flanking Sequence Preferences. Journal of Molecular Biology, 2022, 434, 167482. | 2.0 | 4 |
| 371 | The structural basis of histone modifying enzyme specificity and promiscuity: Implications for metabolic regulation and drug design. Advances in Protein Chemistry and Structural Biology, 2022, 130, 189-243. | 1.0 | 1 |
| 373 | Exploring the Catalytic Mechanism of the RNA Cap Modification by nsp16-nsp10 Complex of SARS-CoV-2 through a QM/MM Approach. International Journal of Molecular Sciences, 2022, 23, 300. | 1.8 | 4 |
| 374 | Histone Methyltransferase DOT1L as a Promising Epigenetic Target for Treatment of Solid Tumors. Frontiers in Genetics, 2022, 13, 864612. | 1.1 | 22 |
| 375 | Smarcb1 Loss Results in a Deregulation of esBAF Binding and Impacts the Expression of Neurodevelopmental Genes. Cells, 2022, 11, 1354. | 1.8 | 2 |
| 376 | Identification and in vitro characterization of a new series of potent and highly selective G9a inhibitors as novel anti-fibroadipogenic agents. Bioorganic and Medicinal Chemistry Letters, 2022, 72, 128858. | 1.0 | 1 |
| 377 | An Epigenetic Role of Mitochondria in Cancer. Cells, 2022, 11, 2518. | 1.8 | 57 |
| 378 | Protein Lysine Methyltransferases Inhibitors. Current Medicinal Chemistry, 2023, 30, 3060-3089. | 1.2 | 0 |
| 379 | The role of protein arginine N-methyltransferases in inflammation. Seminars in Cell and Developmental Biology, 2024, 154, 208-214. | 2.3 | 6 |
| 380 | Polycomb Directed Cell Fate Decisions in Development and Cancer. Epigenomes, 2022, 6, 28. | 0.8 | 8 |
| 381 | Cryo-EM structure-based selection of computed ligand poses enables design of MTA-synergic PRMT5 inhibitors of better potency. Communications Biology, 2022, 5, . | 2.0 | 2 |
| 382 | Antitumor Effect of Demethylzeylasteral (T-96) on Triple-Negative Breast Cancer via LSD1-Mediate Epigenetic Mechanisms. Analytical Cellular Pathology, 2022, 2022, 1-12. | 0.7 | 1 |
| 383 | Mechanistic basis of the increased methylation activity of the SETD2 protein lysine methyltransferase towards a designed super-substrate peptide. Communications Chemistry, 2022, 5, . | 2.0 | 4 |
| 384 | Bispyrrolidinoindoline Epi(poly)thiodioxopiperazines (BPI-ETPs) and Simplified Mimetics: Structural Characterization, Bioactivities, and Total Synthesis. Molecules, 2022, 27, 7585. | 1.7 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 385 | Efficient synthesis of a novel euchromatic histone methyl transferase 2 (G9a) inhibitor. Results in Chemistry, 2022, 4, 100654. | 0.9 | 0 |
| 386 | An updated patent review of protein arginine N-methyltransferase inhibitors (2019â€“2022). Expert Opinion on Therapeutic Patents, 2022, 32, 1185-1205. | 2.4 | 10 |
| 387 | Investigating the functional role of SETD6 in lung adenocarcinoma. BMC Cancer, 2023, 23, . | 1.1 | 2 |
| 388 | Epigenetic Alterations in Canine Malignant Lymphoma: Future and Clinical Outcomes. Animals, 2023, 13, 468. | 1.0 | 2 |
| 389 | A universal fluorescence polarization high throughput screening assay to target the SAM-binding sites of SARS-CoV-2 and other viral methyltransferases. Emerging Microbes and Infections, 2023, 12, . | 3.0 | 4 |
| 390 | Role of histone methylation in skin cancers: Histone methylationâ€“modifying enzymes as a new class of targets for skin cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188865. | 3.3 | 6 |
| 391 | cKMT1 is a New Lysine Methyltransferase That Methylates the Ferredoxin-NADP(+) Oxidoreductase and Regulates Energy Transfer in Cyanobacteria. Molecular and Cellular Proteomics, 2023, 22, 100521. | 2.5 | 1 |
| 393 | Target Class Profiling of Small-Molecule Methyltransferases. ACS Chemical Biology, 2023, 18, 969-981. | 1.6 | 0 |
| 394 | EZH2 Methyltransferase Regulates Neuroinflammation and Neuropathic Pain. Cells, 2023, 12, 1058. | 1.8 | 1 |
| 395 | Epigenetic and Genetics Factors. , 2023, , 320-366. | | 0 |
| 396 | Therapeutic vulnerabilities of cancer stem cells and effects of natural products. Natural Product Reports, 2023, 40, 1432-1456. | 5.2 | 2 |
| 402 | ReACT (redox-activated chemical tagging) chemistry enables direct derivatization and fluorescence detection of S-adenosyl-<scp>l</scp>-homocysteine (SAH). Organic and Biomolecular Chemistry, 2023, 21, 7085-7089. | 1.5 | 0 |